POET TECHNOLOGIES INC. annual report, Q4 FY2020

Full document

POET Technologies Inc. — FY2020 Form 20-F Summary

Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. Financial statements are in U.S. dollars and prepared under IFRS. POET develops its Optical Interposer platform and related photonic products, targeting data-center and telecommunications applications. DenseLight, formerly the principal source of revenue, was sold in November 2019 and is reported as discontinued operations.

Financial performance and position

  • Revenue: The filing reports no 2020 revenue from discontinued operations and provides no clear 2020 product revenue figure for continuing operations. The business was focused on development and commercialization rather than established product sales.
  • Loss and expenses: Net loss from continuing operations was $18.17 million, versus $11.43 million in 2019; basic and diluted loss per share was $0.06, versus $0.04. Operating expenses rose to $14.77 million from $8.78 million, including R&D of $6.63 million (up from $2.08 million) and selling, marketing and administration of $8.14 million (up from $6.70 million). The loss also included a $2.50 million credit loss on the DenseLight sale receivable and $0.94 million of interest expense. There was no 2020 impairment charge; 2019 included $1.76 million of impairment and a $0.29 million income-tax recovery.
  • Margins: No meaningful continuing-operations product margin is presented for 2020. DenseLight’s 2019 discontinued-operations revenue and gross margin were $4.43 million and $3.22 million, respectively, but those results are not comparable to POET’s continuing business.
  • Cash flow: Continuing operating cash use was $9.44 million, broadly level with 2019’s consolidated $9.39 million cash use. Investing activities provided $13.93 million, primarily reflecting $15.50 million collected on the DenseLight sale; financing activities provided $1.16 million. Cash increased by $5.44 million to $6.87 million.
  • Liquidity and balance sheet: Working capital was $2.10 million, down from $15.35 million in 2019. Total assets were $11.64 million, down from $24.08 million, largely because the $18.00 million DenseLight-sale receivable recorded at year-end 2019 was settled or written down. Total liabilities were $5.82 million; shareholders’ equity was $5.81 million.
  • Debt and capital: Convertible debentures were carried at $3.34 million at year-end; they bear 12% annual interest and mature two years from issuance. COVID-19 government loans totaled $0.22 million. POET reported no credit facility. Year-end common shares outstanding were 294.62 million.

Material changes and unusual items

  • POET’s shift to a “fab-light” model and focus on the Optical Interposer followed the 2019 DenseLight divestiture. R&D spending increased substantially in 2020 as activity and costs moved into continuing operations and newer Singapore and Allentown facilities became operational.
  • The DenseLight sale was agreed at $26.00 million. After collecting $15.50 million in 2020 against the remaining receivable, POET accepted partial payments as final and recorded a $2.50 million credit loss.
  • In October 2020, POET signed a joint-venture agreement with Sanan IC to develop and commercialize optical engines through Super Photonics Xiamen (SPX). POET expects to own 48% eventually. The filing describes combined JV contributions of cash, equipment and intellectual property with an estimated value of approximately $50 million; contributions and execution are subject to milestones and other conditions.
  • Subsequent to year-end, POET completed a February 11, 2021 private placement for gross proceeds of $11.81 million, received $8.44 million from option and warrant exercises, and improved liquidity by $1.71 million through debenture conversions. The placement included warrants and therefore potential dilution.

Outlook, commentary and risks

Management said existing cash resources were considered sufficient to fund operating and investing activities beyond one year from issuance of the statements, and that working capital was adequate for the next 12 months. No specific revenue, earnings or production guidance is provided. The plan centers on qualifying Optical Interposer-based products and developing 100G, 200G and 400G optical engines; mass-market adoption depends on customer qualification and design wins, and the filing states that no customer had fully committed to production adoption.

  • Management cited COVID-related supplier backlogs and reduced operating capacity that delayed certain development objectives by 6–8 weeks; the duration and business impact remained uncertain.
  • Key risks include continued losses and operating cash burn, dependence on additional financing, dilution, product-development and customer-qualification uncertainty, intense competition, reliance on suppliers and contract manufacturers, and execution and governance risks in the China-based joint venture.
  • POET also disclosed risks involving intellectual-property protection, export controls and geopolitical uncertainty, and possible repayment of government support loans if eligibility or forgiveness criteria are not met. The company had $0.22 million of COVID-19 loans outstanding and anticipated forgiveness or repayment under applicable program terms.
  • Management assessed disclosure controls and internal control over financial reporting as effective at year-end. The auditor’s opinion covered the financial statements, not the effectiveness of internal controls.

Important facts for investors to verify

  • Whether customer qualification, design wins and production orders have advanced, and whether POET has begun generating material continuing-operations revenue.
  • Actual R&D and cash-burn trends, cash runway, remaining debenture maturities and the use of the February 2021 financing proceeds.
  • SPX’s ownership, milestone funding, capital contributions, product qualification status and commercial sales progress.
  • The final accounting and collection history of the DenseLight sale, including the basis for the $2.50 million credit loss.
  • Potential dilution from outstanding options, warrants, convertible securities and the 2021 financing warrants; also verify the terms and status of COVID-19 loan forgiveness or repayment.